Lenalidomide vs Thalidomide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Cereblon E3 ubiquitin-ligase · full Multiple Myeloma pipeline
Lenalidomide
Marketed by Bristol-Myers Squibb and partners
NCT00056160 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 353 patients with previously treated multiple myeloma and used a hard clinical primary endpoint, time to tumor progression. The primary comparison was met: median TTP was 60.1 weeks (95% CI 41.1–80.0) with lenalidomide plus dexamethasone versus 20.1 weeks (95% CI 16.1–21.1) with placebo plus dexamethasone, a large, clearly favorable separation. The trial's strong design and positive primary result make this high-quality evidence for lenalidomide.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months); Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008) (From randomization up to cut-off date of 02 March 2008; up to 51 months): Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7) (met)
Result source: NCT00424047
Thalidomide
Marketed by Bristol-Myers Squibb
NCT00083551 · Phase 3 · completed
The trial randomly assigned 323 participants to thalidomide and 345 to no thalidomide, but treatment was open-label rather than blinded. Its primary endpoint was the hard clinical outcome of six-year overall survival; although the reported percentages favored thalidomide, statistical significance cannot be determined from the posted registry data.
Next expected readout: August 2027 · NCT00572169 (registry estimate)
Reported efficacy
Overall Survival (6 Years): Overall Survival (6 Years): Thalidomide 65 percentage of participants | No Thalidomide 58 percentage of participants (unclear)
Result source: NCT00083551
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lenalidomide | Thalidomide |
|---|---|---|
| PFS, median | 35.3 vs 21.8+13.5 vs placeboNCT0185052413 other results
| 46.7bNCT025413835 other results
|
| OS, median | 39.3 vs 31.5+7.8 vs placeboNCT000561608 other results
| 49.8bNCT005074162 other results
|
| ORR | 78.5% vs 65.5%vs Lenalidomide + DexamethasoneNCT0123979712 other results
| 73%bNCT005074163 other results
|
| VGPR or better | 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT020760091 other result
| 37%bNCT005074162 other results
|
| MRD negativity | 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT036520645 other results
| —Not posted · NCT00083876 |
PFS, median
- Lenalidomide
- 35.3 vs 21.8+13.5 vs placeboNCT01850524
13 other results
- 31.4 vs 29.5 NCT01335399
- 19.4 vs 14.8 NCT01239797
- 26.3 vs 17.6 NCT01080391
- 25.5 vs 21.2 NCT00689936
- 20.7 vs 21.2 NCT00689936
- 26 vs 21.9 NCT00689936
- 21 vs 21.9 NCT00689936
- 31.4 vs 12.9 NCT00405756
- 14.3 vs 12.9 NCT00405756
- 19.4 vs 14.9 NCT01239797
- 45.3 vs 29.6 NCT02252172
- 25.9 NCT00405756
- 7.5 NCT00405756
- Thalidomide
- 46.7bNCT02541383
5 other results
- 14.7 NCT00507416
- 15.4 NCT00507416
- 17.3 NCT00507416
- 22.5 vs 22.1 NCT01539083
- 52.8 NCT02541383
OS, median
- Lenalidomide
- 39.3 vs 31.5+7.8 vs placeboNCT00056160
8 other results
- 37.4 vs 30.8 NCT00424047
- 67.6 vs 51.8 NCT02076009
- 90.3 vs 64.1 NCT02252172
- 60.4 vs 57.6 NCT01335399
- 48.3 vs 39.6 NCT01239797
- 48.3 vs 40.4 NCT01080391
- 59.1 vs 49.1 NCT00689936
- 62.3 vs 49.1 NCT00689936
- Thalidomide
- 49.8bNCT00507416
2 other results
- 51.5 NCT00507416
- 53.1 NCT00507416
ORR
- Lenalidomide
- 78.5% vs 65.5%vs Lenalidomide + DexamethasoneNCT01239797
12 other results
- 82.5% NCT03859427
- 86.3% NCT03859427
- 82% vs 80% NCT01850524
- 92.9% vs 76.4% NCT02076009
- 92.9% vs 81.6% NCT02252172
- 87.1% vs 66.7% NCT01080391
- 75.1% vs 62.3% NCT00689936
- 73.4% vs 62.3% NCT00689936
- 80.7% vs 67.5% NCT00689936
- 78.6% vs 67.5% NCT00689936
- 91.7% vs 75% NCT02252172
- 62.5% NCT00928486
- Thalidomide
- 73%bNCT00507416
3 other results
- 80% NCT00507416
- 70% NCT00507416
- 81.5% NCT00287872
VGPR or better
- Lenalidomide
- 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT02076009
1 other result
- 81.5% vs 56.9% NCT02252172
- Thalidomide
- 37%bNCT00507416
2 other results
- 51% NCT00507416
- 41% NCT00507416
MRD negativity
- Lenalidomide
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
5 other results
- 60.9% vs 39.4% NCT03652064
- 59% vs 50% NCT01850524
- 32.1% vs 11.1% NCT02252172
- 18.9% NCT03859427
- 18.1% NCT03859427
- Thalidomide
- —Not posted · NCT00083876
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. Lenalidomide: 14 of 14 rows · Thalidomide: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lenalidomide Rows use multiple source trials | Thalidomide Rows use multiple source trials |
|---|---|---|
| Complete responder rate · % of participants | 26% (n=351) vs 14% (n=354) placeboa,b NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 | 53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b NCT01539083 · Phase 3 · registry result, not featured evidence · combination 1 other source trial7.1% (n=112) vs 4.4% (n=113) Thalidomide + Dexamethasone* NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted |
| Duration of Response time to event · months No placebo or comparator arm | NA months20/56 mg/m^2 once weeklyc,a,b NCT03859427 · Phase 3 · registry result, not featured evidence · combination show 1 more doseNA months20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination | 18.3 monthsc,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses19.8 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination 22.4 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination |
| ORR event count · % of participants | 60.5% (n=177) vs 19.3% (n=176) placebo*a,b NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 107 Participants as posted | 37.1% (n=35) vs 0% (n=33) ZLD @ 52wk*a,b NCT00432458 · Phase 3 · registry result, not featured evidence · combination · converted to % from 13 participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 82.5% (n=228)20/56 mg/m^2 once weeklyc,a,b NCT03859427 · Phase 3 · registry result, not featured evidence · combination show 1 more dose86.3% (n=226)20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination | 73% (n=147)c,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses70% (n=145) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 80% (n=133) NCT00507416 · Phase 3 · registry result, not featured evidence · combination |
| Overall Survival time to event · months No placebo or comparator arm | NA months20/56 mg/m^2 once weeklyc,a,b NCT03859427 · Phase 3 · registry result, not featured evidence · combination show 1 more doseNA months20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination | 49.8 monthsc,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses53.1 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination 51.5 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 7.45 months*c,a,d,b NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 32.3 weeks as posted show 1 more dose25.85 months* NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 112 weeks as posted | 52.8 monthsc,a,d,b NCT02541383 · Phase 3 · registry result, not featured evidence show 1 more dose46.7 months NCT02541383 · Phase 3 · registry result, not featured evidence |
| Stringent Complete responder rate · % of participants | 35.6% (n=368) vs 15.7% (n=369) Lenalidomide + Dexamethasonea,b NCT02252172 · Phase 3 · registry result, not featured evidence · combination | 28.6% (n=98) vs 26% (n=96) Thalidomide + Prednisolone @ 52wka,b NCT01539083 · Phase 3 · registry result, not featured evidence · combination |
| Time to Progression time to event · months | 13.87 vs 4.64 placebo months*a,b NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 60.1 weeks as posted 7 other source trials12.02 vs 4.64 placebo months* NCT00424047 · Phase 3 · combination · converted to months from 52.1 weeks as posted 12.09 vs 4.64 placebo months* NCT00424047 · Phase 3 · combination · converted to months from 52.4 weeks as posted NA vs 18.43 Lenalidomide, Low-dose Dexamethasone months NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 NA vs 40.87 Lenalidomide + Dexamethasone months NCT02252172 · Phase 3 · registry result, not featured evidence · combination 45.8 vs 26.8 placebo months NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 14.47 vs 14.15 MPp+p months* NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 62.7 weeks as posted 34.18 vs 14.15 MPp+p months* NCT00405756 · Phase 3 · registry result, not featured evidence · combination · converted to months from 148.1 weeks as posted | 28.8 vs 14.4 ZLD months*a,b NCT00432458 · Phase 3 · registry result, not featured evidence · combination · converted to months from 2.4 years as posted 1 other source trial13.4 vs 19.19 Thalidomide + Dexamethasone months* NCT00097981 · Phase 3 · registry result, not featured evidence · combination · converted to months from 408 days as posted |
| Time to Response time to event · months No placebo or comparator arm | 1 months20/56 mg/m^2 once weeklyc,e,a,b NCT03859427 · Phase 3 · registry result, not featured evidence · combination show 1 more dose1 months20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination | 2 monthse,a,b NCT00287872 · Phase 2 · registry result, not featured evidence · combination |
| Time to Treatment Failure time to event · months | 17.2 vs 14.1 Melphalan + Prednisone + Thalidomide monthsc,a,b NCT00689936 · Phase 3 · registry result, not featured evidence · combination show 3 more doses17.2 vs 14.1 Melphalan + Prednisone + Thalidomide months NCT00689936 · Phase 3 · registry result, not featured evidence · combination 16.9 vs 14.1 Melphalan + Prednisone + Thalidomide months NCT00689936 · Phase 3 · registry result, not featured evidence · combination 16.9 vs 14.1 Melphalan + Prednisone + Thalidomide months NCT00689936 · Phase 3 · registry result, not featured evidence · combination | 16.5 vs 11.1 ZLD monthsa,b NCT00432458 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 63.8%f NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results— NCT00424047 · Phase 3 · combination n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 n/a: no completion milestone NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 n/a: no completion milestone NCT02252172 · Phase 3 · registry result, not featured evidence · combination 16.2%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 49.3%Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.8% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.6% NCT01239797 · Phase 3 · registry result, not featured evidence · combination 0% NCT02322320 · Phase 3 · registry result, not featured evidence 0% NCT01109004 · Phase 3 · registry result, not featured evidence 1% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneMPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneMPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination 0% NCT01621672 · Phase 3 · registry result, not featured evidence —Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneLenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 40% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 56.4% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 51.3% NCT00478777 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT00179647 · Phase 3 · registry result, not featured evidence 0% NCT02969837 · Phase 2 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence 6.1% NCT03477539 · Phase 2 · registry result, not featured evidence 5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination | 0%g NCT00083551 · Phase 3 · combination show 20 more results—DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 20.7%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 0.6% NCT00049673 · Phase 3 · registry result, not featured evidence 70.2%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.3%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 74.9%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT00432458 · Phase 3 · registry result, not featured evidence · combination 89.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT01632150 · Phase 2 · registry result, not featured evidence · combination — NCT00040937 · Phase 2 · registry result, not featured evidence · combination 0% NCT00081939 · Phase 2 · registry result, not featured evidence 0% NCT00083382 · Phase 2 · registry result, not featured evidence · combination 11.1% NCT00458705 · Phase 2 · registry result, not featured evidence · combination 0% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 19.8%f NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results— NCT00424047 · Phase 3 · combination — NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 — NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 — NCT02252172 · Phase 3 · registry result, not featured evidence · combination —20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0% NCT01239797 · Phase 3 · registry result, not featured evidence · combination — NCT02322320 · Phase 3 · registry result, not featured evidence — NCT01109004 · Phase 3 · registry result, not featured evidence — NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination 13.1%Lenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination 12.7%Lenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination 20.4%MPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination 17.6%MPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination — NCT01621672 · Phase 3 · registry result, not featured evidence —Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence —Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 8% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 19.3% NCT00478777 · Phase 3 · registry result, not featured evidence · combination 15.4% NCT00179647 · Phase 3 · registry result, not featured evidence — NCT02969837 · Phase 2 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence — NCT03477539 · Phase 2 · registry result, not featured evidence — NCT05032820 · Phase 2 · registry result, not featured evidence · combination | —g NCT00083551 · Phase 3 · combination show 20 more results—DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 5.5%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination — NCT00049673 · Phase 3 · registry result, not featured evidence 34.5%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 38.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 40.1%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination — NCT00432458 · Phase 3 · registry result, not featured evidence · combination 39.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination 17.5% NCT01632150 · Phase 2 · registry result, not featured evidence · combination — NCT00040937 · Phase 2 · registry result, not featured evidence · combination — NCT00081939 · Phase 2 · registry result, not featured evidence — NCT00083382 · Phase 2 · registry result, not featured evidence · combination 8.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination — NCT00287872 · Phase 2 · registry result, not featured evidence · combination —1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination —800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination —600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 62.7%f NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 33 more results59.7% NCT00424047 · Phase 3 · combination 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence — NCT03941860 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 72.4% NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 79.4% NCT02252172 · Phase 3 · registry result, not featured evidence · combination 37.7%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 32.5%20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —Ixazomib + LenDex NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 65.4%Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 73%Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 79% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 74.8% NCT01239797 · Phase 3 · registry result, not featured evidence · combination 6.7% NCT02322320 · Phase 3 · registry result, not featured evidence 20.6% NCT01109004 · Phase 3 · registry result, not featured evidence 65.3% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 57%Lenalidomide and Dexamethasone (Rd NCT00689936 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide and Dexamethasone Rd1 NCT00689936 · Phase 3 · registry result, not featured evidence · combination 71.1%Lenalidomide and Low-Dose Dexameth NCT00689936 · Phase 3 · registry result, not featured evidence · combination 44%MPR+R NCT00405756 · Phase 3 · registry result, not featured evidence · combination 40.8%MPR+p NCT00405756 · Phase 3 · registry result, not featured evidence · combination 72% NCT01621672 · Phase 3 · registry result, not featured evidence 23.8%Lenalidomide ( ExtensionPhase) 22 NCT00622336 · Phase 3 · registry result, not featured evidence 53.6%Lenalidomide (Treatment Phase) Up NCT00622336 · Phase 3 · registry result, not featured evidence 42.7%Lenalidomide and Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination —Lenalidomide+Dexamethasone NCT00064038 · Phase 3 · registry result, not featured evidence · combination 48% NCT00928486 · Phase 3 · registry result, not featured evidence · combination 57.9% NCT00420849 · Phase 3 · registry result, not featured evidence · combination 54.9% NCT00478777 · Phase 3 · registry result, not featured evidence · combination 45.9% NCT00179647 · Phase 3 · registry result, not featured evidence 39.1% NCT02969837 · Phase 2 · registry result, not featured evidence 13.3% NCT02619682 · Phase 2 · registry result, not featured evidence 26.5% NCT03477539 · Phase 2 · registry result, not featured evidence 22.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination | 100%g NCT00083551 · Phase 3 · combination show 20 more results49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 34.6%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination 27.2%Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 3% NCT00049673 · Phase 3 · registry result, not featured evidence 53.3%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 50.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 58.2%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 8.6% NCT00432458 · Phase 3 · registry result, not featured evidence · combination 50% NCT00097981 · Phase 3 · registry result, not featured evidence · combination — NCT01632150 · Phase 2 · registry result, not featured evidence · combination 1.3% NCT00040937 · Phase 2 · registry result, not featured evidence · combination 100% NCT00081939 · Phase 2 · registry result, not featured evidence 19.3% NCT00083382 · Phase 2 · registry result, not featured evidence · combination 48.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 0%1000 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 33.3%600 mg NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | f fatigue 64.4% (placebo 60%) neutropenia 49.2% (placebo 6.9%) diarrhoea 48% (placebo 30.3%) NCT00056160 · Phase 3 · combination · Multiple Myeloma · phase 3 show 27 more resultsconstipation 40.3% (placebo 23.4%) neutropenia 40.3% (placebo 9.7%) diarrhoea nos 38.1% (placebo 25.7%) NCT00424047 · Phase 3 · combination diarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence neutropenia 65.4% diarrhoea 59.7% upper respiratory tract infection 43.5% NCT02076009 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 65.1% neutropenia 61.5% fatigue 44.8% NCT02252172 · Phase 3 · registry result, not featured evidence · combination 20/56 mg/m^2 once weekly neutropenia 29.1% anaemia 25.1% hypertension 21.5% NCT03859427 · Phase 3 · registry result, not featured evidence · combination 20/27 mg/m^2 twice weekly neutropenia 31.6% hypertension 24.2% anaemia 23.8% NCT03859427 · Phase 3 · registry result, not featured evidence · combination diarrhoea 77% (placebo 30%) oedema peripheral 55.5% (placebo 32.5%) constipation 48.2% (placebo 38.1%) NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 41.7% (placebo 30%) oedema peripheral 40.5% (placebo 32.5%) constipation 36.2% (placebo 38.1%) NCT01850524 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 51.8% fatigue 49.3% oedema peripheral 43.9% NCT01335399 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 diarrhoea 50% fatigue 48.4% anaemia 42.5% NCT01239797 · Phase 3 · registry result, not featured evidence · combination diarrhoea 43.4% anaemia 42.3% neutropenia 40.1% NCT01080391 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 constipation 38.9% diarrhoea 38% anaemia 35.4% NCT00689936 · Phase 3 · registry result, not featured evidence · combination diarrhoea 46.6% anaemia 44.5% constipation 43.8% NCT00689936 · Phase 3 · registry result, not featured evidence · combination neutropenia 78% thrombocytopenia 68.7% anaemia 66% NCT00405756 · Phase 3 · registry result, not featured evidence · combination neutropenia 76.3% thrombocytopenia 65.8% anaemia 59.9% NCT00405756 · Phase 3 · registry result, not featured evidence · combination grade 1 hypoalbuminemia 68% grade 1 thrombocytopenia 52% grade 2 leukopenia 36% NCT01621672 · Phase 3 · registry result, not featured evidence asthenia 14.3% headache 14.3% anaemia nos 9.5% NCT00622336 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 77.1% hemoglobin 64.6% glucose, serum-high (hyperglycemia) 55.2% NCT00064038 · Phase 3 · registry result, not featured evidence · combination neutropenia 80% lymphopenia 64% leukopenia 60% NCT00928486 · Phase 3 · registry result, not featured evidence · combination fatigue 42.4% neutropenia 41.4% muscle spasms 34.4% NCT00420849 · Phase 3 · registry result, not featured evidence · combination muscle spasms 24.3% fatigue 22.9% leukopenia 19.4% NCT00478777 · Phase 3 · registry result, not featured evidence · combination fatigue 56% neutropenia 32.3% muscle cramp 25.6% NCT00179647 · Phase 3 · registry result, not featured evidence fatigue 63% diarrhea 45.7% edema limbs 37% NCT02969837 · Phase 2 · registry result, not featured evidence lymphocyte decreased 36.7% lymphocyte decreased 33.3% wbc decreased 33.3% NCT02619682 · Phase 2 · registry result, not featured evidence platelet count decreased 93.9% anemia 91.8% neutrophil count decreased 83.7% NCT03477539 · Phase 2 · registry result, not featured evidence lymphocyte count decreased 85% neutrophil count decreased 77.5% white blood cell decreased 72.5% NCT05032820 · Phase 2 · registry result, not featured evidence · combination | g grade 1 bicarbonate decrease 60.1% (placebo 62.9%) grade 1 hypokalemia 54.2% (placebo 52.8%) grade 3 anemia (hgb) 49.8% (placebo 50.4%) NCT00083551 · Phase 3 · combination show 19 more resultsperipheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence constipation 35.8% nausea 32.3% peripheral sensory neuropathy 24.4% NCT01539083 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 37.9% peripheral sensory neuropathy 36.9% neuropathy peripheral 29.1% NCT01539083 · Phase 3 · registry result, not featured evidence · combination neuropathy-sensory 89.1% (placebo 43.6%) fatigue 72.7% (placebo 58.3%) bone pain 72.1% (placebo 74.2%) NCT00049673 · Phase 3 · registry result, not featured evidence insomnia 5.5% weight decreased 2.4% blood sodium decreased 1.8% NCT00507416 · Phase 3 · registry result, not featured evidence · combination leukopenia 7.4% platelet count decreased 4.3% insomnia 3.7% NCT00507416 · Phase 3 · registry result, not featured evidence · combination hyperuricaemia 5.1% insomnia 3.8% cough 3.2% NCT00507416 · Phase 3 · registry result, not featured evidence · combination peripheral sensory neuropathy 80% fatigue 77.1% constipation 62.9% NCT00432458 · Phase 3 · registry result, not featured evidence · combination oedema peripheral 56.6% fatigue 54.7% constipation 45.3% NCT00097981 · Phase 3 · registry result, not featured evidence · combination sensory neuropathy 78.9% fatigue/malaise/lethargy 68.4% hyperglycemia 51.3% NCT00040937 · Phase 2 · registry result, not featured evidence · combination grade 1 bicarbonate decrease 72.3% grade 2 hypoalbuminemia 68.6% grade 1 alkaline phosphatase increase 59.7% NCT00081939 · Phase 2 · registry result, not featured evidence grade 1 hypomagnesemia 56.6% grade 2 fatigue 50.6% grade 1 hypocalcemia 47% NCT00083382 · Phase 2 · registry result, not featured evidence · combination thrombosis/thrombus/embolism 17.8% constipation 11.1% diarrhea 8.9% NCT00458705 · Phase 2 · registry result, not featured evidence · combination peripheral neuropathy 83.3% fatigue 73.3% constipation 63.3% NCT00287872 · Phase 2 · registry result, not featured evidence · combination 1000 mg somnolence 100% dysgeusia 66.7% febrile neutropenia 66.7% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 800 mg diarrhea 100% nausea 100% somnolence 100% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination 600 mg somnolence 100% diarrhea 66.7% mucositis 66.7% NCT01242267 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 3 versus Phase 2.
- fPopulation comparability has not been reviewed for 26 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lenalidomide
show 11 more results
show 1 more result
show 3 more results
show 1 more result
show 9 more results
show 7 more results
show 6 more results
+ 116 further endpoints in the CSV export.
Thalidomide
show 2 more results
show 2 more results
show 2 more results
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenalidomide's landscape · Thalidomide's landscape